Overview The NIAMS Clinical Trial Working Group was established to consider how the institute could optimally solicit and fund applications for clinical trials that would have the greatest impact in improving clinical outcomes, whether of rare or common diseases, for people with diseases and/or conditions within the NIAMS mission. Please

NIAMS promotes interdisciplinary research and partnerships, uniting diverse fields, NIH agencies, and communities to advance care for bone, joint, muscle, and skin diseases.

Overview While the success of antiretroviral therapies continues to improve the life expectancy of people living with HIV/AIDS (PLWHA), both aging and HIV-treatment are associated with the early appearance or greater risk of comorbidities that affect the musculoskeletal system and skin. In order to address the mechanisms underlying these changes

Back pain is one of the most common medical problems in the United States. Changes to any part of your back—such as ones that may occur with aging, getting hurt, or having other medical conditions—can lead to back pain. It can start suddenly or come on slowly. It may feel like a dull, constant ache, or a sudden, sharp pain.

Peer review of properly completed applications submitted in response to the Program Announcements will be conducted by the NIAMS AMS Clinical Trials Review Committee. This review committee will provide expertise in NIAMS disease areas and in clinical trial methodology.

NIAMS' activities within data science, bioinformatics, data sharing policy and compliance, and emerging technologies.

The NIAMS FY 2025–2029 Plan outlines 4 goals, 10 priorities, and a commitment to equitable research and workforce support to improve human health outcomes.